Tandem Diabetes Care, Inc. (FRA:TD5A)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.09B -20.6% |
| Revenue (ttm) | 891.18M +4.5% |
| Net Income | -82.00M |
| EPS | -1.21 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 15.90 |
| Previous Close | 16.40 |
| Day's Range | 15.90 - 15.90 |
| 52-Week Range | 8.79 - 23.09 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About Tandem Diabetes Care
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, it offers Tandem Device Updater used to update the pump software from a pe... [Read more]
Financial Performance
In 2025, Tandem Diabetes Care's revenue was $1.01 billion, an increase of 7.93% compared to the previous year's $940.20 million. Losses were -$204.71 million, 113.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
Wells upgrades Tandem Diabetes on ‘transformational’ pharmacy model
Wells Fargo last night upgraded Tandem Diabetes (TNDM) to Overweight from Equal Weight with a price target of $27, up from $21. The company’s pharmacy model is “transformational and de-risking…
Tandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo upgraded Tandem Diabetes (TNDM) to Overweight from Equal Weight with a $27 price target
Tandem Diabetes price target lowered to $17 from $22 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Tandem Diabetes (TNDM) to $17 from $22 and keeps a Neutral rating on the shares. The firm updated models in…
Tandem Diabetes price target lowered to $21 from $24 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Tandem Diabetes (TNDM) to $21 from $24 and keeps a Neutral rating on the shares. MedTech has experienced one of its weakest…
Tandem Diabetes Care Transcript: AGM 2026
The meeting covered six key proposals, including director elections, executive compensation, and amendments to governance documents. All proposals passed, and no questions were raised on meeting matters.
Tandem Diabetes price target lowered to $25 from $35 at BofA
BofA lowered the firm’s price target on Tandem Diabetes (TNDM) to $25 from $35 and keeps a Neutral rating on the shares. After having hosted 34 medtech companies last week…
Tandem Diabetes Care Transcript: Bank of America Global Healthcare Conference 2026
Record Q1 results were achieved amid major business model changes, including the PayGo pharmacy launch and direct international sales. Pharmacy channel coverage is expanding, new product launches like Mobi are set to drive growth, and profitability is improving with strong customer retention.
Tandem Diabetes initiated with a Hold at Benchmark
Benchmark analyst Bruce Jackson last night initiated coverage of Tandem Diabetes (TNDM) with a Hold rating and no price target The company is undertaking an “ambitious strategy” to simultaneously shif...
Tandem Diabetes initiated with a Hold at Benchmark
Benchmark initiated coverage of Tandem Diabetes (TNDM) with a Hold rating.
Tandem Diabetes price target lowered to $55 from $56 at Barclays
Barclays lowered the firm’s price target on Tandem Diabetes (TNDM) to $55 from $56 and keeps an Overweight rating on the shares.
Tandem Diabetes price target raised to $24 from $22 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Tandem Diabetes (TNDM) to $24 from $22 and keeps a Neutral rating on the shares.
Tandem Diabetes Care Earnings Call Transcript: Q1 2026
Record Q1 pump shipments and sales, margin expansion, and strong cash flow marked the quarter. Key launches and direct international expansion support reaffirmed 2026 guidance, despite ongoing infusion set supply challenges.
Tandem Diabetes Care Earnings release: Q1 2026
Tandem Diabetes Care released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Tandem Diabetes Care Quarterly report: Q1 2026
Tandem Diabetes Care has published its Q1 2026 quarterly earnings report on May 7, 2026.
Tandem Diabetes Care Slides: Q1 2026
Tandem Diabetes Care has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Tandem Diabetes Care Announces First Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2...
Tandem Diabetes Care Announces Upcoming Conference Presentations
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the ...
Tandem announces U.S. FDA cleared Control-IQ+ AID tech for use in pregnancy
Tandem Diabetes (TNDM) Care announced that the United States Food and Drug Administration, FDA, has cleared Control-IQ+ automated insulin delivery, AID, technology for use in pregnancy complicated by ...
Tandem Diabetes Care's Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--FDA clears Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy for people with type 1 diabetes.
Tandem Diabetes price target raised to $45 from $36 at Rothschild & Co Redburn
Rothschild & Co Redburn analyst Issie Kirby raised the firm’s price target on Tandem Diabetes (TNDM) to $45 from $36 and keeps a Buy rating on the shares, offering over…
Tandem Diabetes price target raised to $28 from $25 at TD Cowen
TD Cowen raised the firm’s price target on Tandem Diabetes (TNDM) to $28 from $25 and keeps a Buy rating on the shares. The firm updated its model to map…
Tandem Diabetes price target raised to $28 from $25 at TD Cowen
TD Cowen raised the firm’s price target on Tandem Diabetes (TNDM) to $28 from $25 and keeps a Buy rating on the shares. The firm updated its model to map…
Tandem Diabetes Care Proxy statement: Proxy filing
Tandem Diabetes Care filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Tandem Diabetes Care Proxy statement: Proxy filing
Tandem Diabetes Care filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Citi adds ‘upside 90-day catalyst watch’ on Tandem Diabetes
Citi analyst Joanne Wuensch added an “upside 90-day catalyst watch” on Tandem Diabetes (TNDM) while keeping a Neutral rating on the shares with a $22 price target The firm believes…